CoreWeave may offer and sell up to 35,000,000 Class A common shares through sales agents or forward sellers under an agreement dated September 17, 2026. Net proceeds, if any, may support Debt repayment, operating expenses, Capital spending, acquisitions and other general corporate purposes.
Key Highlights
- The company’s authorized Capital Stock includes 3,000,000,000 Class A shares and 100,000,000 preferred shares.
- Sales agents or their affiliates may receive 5% or more of net proceeds in certain forward-sale transactions, creating a FINRA Rule 5121 conflict of interest.
- The offering covers up to 35,000,000 shares of Class A common stock.
The shares may be issued directly through sales agents or sold as borrowed shares through forward sellers under collared forward sale agreements.
35 Million-Share Offering Structure
Deutsche Bank Securities, Goldman Sachs, J.P. Morgan, Jefferies and Morgan Stanley are among the institutions serving as sales agents under the agreement. Forward purchasers may elect settlement dates between a first acceleration date and the applicable scheduled Maturity date. At settlement, CoreWeave (NASDAQ: CRWV) will deliver the shares underlying the relevant forward transaction and receive consideration based on the applicable pricing terms. The forward hedge selling commission rate may be no greater than 2.0%. The company said net proceeds, after commissions and offering expenses, may be used for general corporate purposes. Those purposes include repayment of indebtedness, operating expenses, capital expenditures, investments in subsidiaries, acquisitions and support for its objective of moving its enterprise Credit profile toward Investment grade.
Share Count and Capital Structure
CoreWeave had 458,871,690 Class A shares outstanding as of July 31, 2026. The company’s authorized capital stock includes 3,000,000,000 Class A shares, 200,000,000 Class B shares, 200,000,000 Class C shares and 100,000,000 undesignated preferred shares, each with a $0.000005 par value. The outstanding-share figure excludes 23,641,274 shares issuable under stock options, 14,221,812 shares tied to restricted stock units under the 2019 Plan, 15,106,561 shares tied to restricted stock units under the 2025 Plan and 11,864,667 shares issuable upon Warrant exercises. A further 77,262,262 shares are reserved for future issuance under Equity compensation plans, including 62,503,685 under the 2025 Plan and 14,758,577 under the 2025 Employee Stock Purchase Plan. Those circumstances are treated as a conflict of interest under FINRA Rule 5121.



Please wait processing your request...